Care for Transgender Patient: Providing Competent and Compassionate Care During a Time of Transition

Similar documents
Transgender Medicine beyond the guidelines.

HEALTH: Presented by: Alsean R. Bryant, Pharm.D., AAHIVP AIDS Healthcare Foundation

Hormone Therapy Overview for the Behavioral Health Provider. Julie Thompson, PA Fenway Health

Transgender Medicine: Essentials for the Primary Care Provider BENJAMIN J. BOH, DO, MS

HEALTH CARE FOR TRANSGENDER PERSONS

8/17/2015. Objectives. Disclosures

Disclosures. Endocrine Care of the Transgender Patient. Objectives. Start where you are. Use what you have. Do what you can. Vocabulary.

Pharmacy Policy. Adult transgender hormonal therapy may be approved when all of the following criteria are met:

Guidelines for the Clinical Care of Persons with Gender Dysphoria

What to Know a 21 st Century Approach to Transgender Medical Care

Endocrinology and the Transgender Patient

State of California, California Health and Human Services Agency, Department of Managed Health Care 2013:

Arti Barnes MD MPH Tuesday AM series ENCOMPASSING THE MARGINALIZED: CARE FOR THE TRANSGENDER COMMUNITY

Guidelines for the Clinical Care of Persons with Gender Dysphoria

19 YO F W/GENDER IDENTITY DISORDER. Jess Hwang, Endocrinology fellow 6/5/14

Gender Health Center, Hormone Clinic th St #201 Sacramento, CA 95817

Harold Husovsky, MD. Associate Professor of General Medicine at SUNY Health Science Center

MEDICAL POLICY No R1 GENDER REASSIGNMENT SURGERY

Gender Confirming Healthcare Across the Lifespan. Dr. Tracey Wiese, APRN, FNP-BC, PMHNP-BC

CITY AND COUNTY OF SAN FRANCISCO

Hypogonadism 4/27/2018. Male Hypogonadism -- Definition. Epidemiology. Objectives HYPOGONADISM. Men with Hypogonadism. 95% untreated.

Patient education for transgender masculinizing hormone therapy

Providing Primary Care for Gender-Diverse Clients. Seaway Valley Community Health Centre June 30 th, 2016 Jennifer Douek, Jordan Zaitzow

Transgender Medical Benefits

Testosterone Therapy in Men with Hypogonadism

Transgender Populations

Fertility Issues for Transgender Persons. Timothy Cavanaugh, MD Fenway Health

GENder Education and Care Interdisciplinary Support (GENECIS) Feminizing Medications for Patients with Gender Dysphoria

Pharmacists' role in pharmacotherapy management of transgender patients

Prescribing Guidelines

10/07/18. Conflict of interest statement

GUIDELINES FOR THE USE OF FEMINISING HORMONE THERAPY IN GENDER DYSPHORIA. Information for Primary Care December 2015 (Review Date June 2016)

North of Tyne and Gateshead Area Prescribing Committee GUIDELINES FOR THE USE OF FEMINISING HORMONE THERAPY IN GENDER DYSPHORIA

Information About Hormonal Treatment for Trans men

Jamie Feldman M.D., Ph.D. Dept. of Family Medicine/Program in Human Sexuality University of Minnesota

Transgender Health Cases from the Transgender and Intersex Specialty Care Clinic

Case Studies in Primary care

TRANSGENDER HEALTHCARE Barry Zevin, MD Conrad Wenzel, MSW

National Gender Identity Clinical Network for Scotland (NGICNS)

Patient education for transgender feminizing hormone therapy

Endocrine Treatment of Gender-Dysphoric/ Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guideline. Education Module June, 2017

Corporate Medical Policy

Meeting the Health Care Needs of Transgender People. Presenter: Julie Thompson, PA Fenway Health Boston, MA 18 November 2015

Class Review: Cross sex Hormone Therapy

Male Hypogonadism. Types and causes of hypogonadism. What is male hypogonadism? Symptoms. Testosterone production. Patient Information.

CLIENT INFORMATION and INFORMED CONSENT TESTOSTERONE THERAPY

Horizon BCBSNJ Uniform Medical Policy Manual Policy Number: 115 Effective Date: 01/01/2017

Medical Policy. Transgender Reassignment Surgery. Policy Number: Policy History

NHS MEDICAL POLICY. Transgender Surgical Procedures Procedure

Medical Necessity Guidelines: Transgender Surgical Procedures

There are four areas where you can expect changes to occur as your hormone therapy progresses.

Transgender Health and Primary Care. Leon L. Lai, MD and Veronica Gomez-Lobo, MD Medstar Washington Hospital Center November 4, 2017

Transgender: A broad spectrum of individuals who transiently or persistently identify with a gender different from their natal gender.

Please note that this should only be used for feedback and comments specifically related to this particular medical policy.

Cross-Sex Hormone Therapy. Timothy Cavanaugh, MD Medical Director for Trans Health Team Fenway Health

There are four areas where you can expect changes to occur as your hormone therapy progresses. 1) Physical

Integrating Transgender Health Care Into Our Medical Culture

Caring for Trans and Gender Diverse Clients in BC: A Primary Care Toolkit

TESTOSTERONE DEFINITION

Addressing Primary Care Preventive Needs of Transgender Patients. Julie Thompson, PA Fenway Health

Gender Identity Services

Values Accountability Integrity Service Excellence Innovation Collaboration

Primary Care and Preventive Health Needs of Transgender Patients. Julie Thompson, PA-C Fenway Health

Class Review: Cross sex Hormone Therapy

Division: Medical Management Department: Utilization Management

MODULE 1 F E M I N I Z I N G

Cross-Sex Hormone Therapy. Timothy Cavanaugh, MD Medical Director for Trans Health Program Fenway Health

Trust Women Seattle Client Information for Informed Consent MASCULIZING MEDICATIONS FOR TRANSGENDER CLIENTS

Coding... 4 Benefit Application... 6 Description of Services... 7 Clinical Evidence... 8

Case 5:12-cv M Document 118 Filed 07/31/14 Page 1 of 11 IN THE UNITED STATES DISTRICT COURT FOR THE WESTERN DISTRICT OF OKLAHOMA

Information on Testosterone Therapy

Transgender. Transgender Health and HIV. Transgender Terminology. Gender Identity & Sexual Orientation 12/8/17

Oestrogen, progestogens and assessing risks of hormones. Dr Naomi Achong BSc MBBS(Hons) FRACP Endocrinologist

Client Information for Informed Consent FEMINIZING MEDICATIONS FOR TRANSGENDER CLIENTS

Primary Care of LGBT Patients

-There are 2 aspects of sex: genetic sex and anatomical sex. In women, the sex chromosomes are XX. In men, the sex chromosomes are XY.

Transgender Treatment in High Risk Adolescents

Transgender Medicine in Primary Care. John-Paul Bettencourt, D.O., M.P.H., AAHIVS

The Adolescent: A Patient at Risk: Ovarian Failure in Adolescent Cancer Survivors

Guidelines for Preventative Health Care in LGBT Populations

Trans Affirming Letter Writing: Best Practices and Challenges for BHP. Justin Wheeler, LISW-S Michelle Pride, Ph.D.

Breast implants Breast reduction surgery Breast biopsy Breast lumpectomy Chest reconstruction Other:

Primary Care for Transgender Pa5ents. Objec5ves. Transgender 2/22/17. Charleston APRN Conference February 2017

Clinical evaluation of infertility

Information on Feminizing Medications

1. Has this plan authorized this medication in the past for this member (i.e., previous authorization is on file under this plan)?

2.0 Synopsis. Lupron Depot M Clinical Study Report R&D/09/093. (For National Authority Use Only) to Part of Dossier: Name of Study Drug:

Primary and HIV Care for Our Transgender Patients

Evidence Based Approach to Screening Transgender and Gender-diverse (TGD) Adults. Denise Rizzolo, PhD, PA-C

Informed Consent Form for Feminizing Medications

Evaluation and Treatment of Primary Androgen Deficiency Syndrome in Male Patients

DISCLOSURES LEARNING OBJECTIVES. 21st Century Strategies: Transgender Hormone Care. Patient/PCP. Medical model

Department of Pediatrics

2017 HIV Clinical Update. Gender-Affirming Hormone Therapy in the Context of HIV Prevention and Treatment. Learning objectives.

Endocrine Treatment of Transsexual Persons Page 1 of 72. Louis J. Gooren, Walter J. Meyer III, Norman P. Spack, Vin Tangpricha, and Victor M.

Information About Hormonal Treatment for Trans women

Questions of Definition

Transcription:

Care for Transgender Patient: Providing Competent and Compassionate Care During a Time of Transition Jessica Francis, MD Assistant Professor Department of Obstetrics and Gynecology Froedtert and the Medical College of Wisconsin

Objectives To review guidelines for establishing care of transgender patients To review screening questions and special considerations for transgender patients To review options for transgender medical and surgical transition

Disclosures I have no relevant financial relationships to disclose.

The image part with relationship ID rid2 was not found in the file.

Doctors can kind of go two ways, right? You can either see a whole bunch of life and decide that there s no point in being judgmental everyone s different and, you know, everyone s got their own path in life and not to judge people or you can just get really narrow-minded and somehow build this construct between us and them, with them being the patients. I think one issue that concerns me is the lack of training and /or exposure that med students and residents have to the transgendered population and indeed the general population of people, you know often will think they ve never met a trans person. Well many of them have. So you know the feeling that well this doesn t affect my practice or my life perpetuates the idea that there s just no need for training around Trans issues. What I ve had to do is rely on the patient to tell me how best to manage, and not that I m averse to that, but that s pretty suboptimal when patients have to tell doctors, you know, how to do what we should know how to do. Snelgrove, 2012

LGBT Statistics LGBT youth are 2-3 x more likely to attempt suicide LGBT youth are more likely to be homeless Transgender individuals have a high prevalence of HIV/STDs, victimization, mental health issues, and suicide and are less likely to have health insurance than heterosexual or LGB individuals. LGBT populations have the highest rates of tobacco, alcohol, and other drug use Healthy People 2020

School Victimization Lesbian, gay, bisexual, and transgender-related school victimization is strongly linked to young adult mental health and risk for STDs and HIV There is no strong association with substance use or abuse. Elevated levels of depression and suicidal ideation among males can be explained by their high rates of LGBT school victimization Russell, 2011

The image part with relationship ID rid2 was not found in the file. Home Life Approximately 30% of LGBT youth report physical abuse by a family member because of sexual orientation or gender identity/expression Minorityhealth.hhs.gov

Childhood vs Adolescence Adolescent Much higher rate of persistence than in children One study of 70; all persisted Ratio of male:female is 1:1 Child Dysphoria persists in 6-27% Boys more likely to identify as gay in adulthood Ratio of male:female is 6:1 to 3:1 WPATH SOC

Phenomenology in Children Features can develop as young as age 2 Express discomfort with body Express desire to be the other sex Prefer clothing/toys/games commonly associated with the other sex Prefer playing with other sex peers Uncommon to also express anxiety or depression

The image part with relationship ID rid3 was not found in the file. Phenomenology in Adolescents May have intensity of feelings at time of puberty as secondary sex characteristics develop Many do not report a history of childhood gendernonconforming behaviors

Barriers to Providing Care Survey of 184 physicians: The majority of physicians would not regularly discuss sexual orientation, sexual attraction, or gender identity while taking a sexual history from a sexually active adolescent. The majority of physicians would not ask patients about sexual orientation if an adolescent presented with depression, suicidal thoughts, or had attempted suicide. If an adolescent stated that he or she was not sexually active, 41% of physicians reported that they would not ask additional sexual health-related questions. Only 57% agreed to an association between being a LGBTQ adolescent and suicide. The majority of physicians did not believe that they had all the skills they needed to address issues of sexual orientation with adolescents, and that sexual orientation should be addressed more often with these patients and in the course of training.

Barriers to Providing Care Lack of appropriate accommodations in outpatient and inpatient setting Scheduling difficulties Lab Surgical Lack of specific training opportunities Personal belief structure

Barriers to Receiving Care Over represented in the foster care system Abandonment/abuse in system or with family Often wind up homeless One in five transgender people will find themselves in need of homeless shelter assistance Health care provider discomfort may alienate patients and result in low quality or inappropriate care May deter from seeking additional care

Initial Evaluation Discuss support structure Screen for risk status Discuss online support venues and safety Screen for school performance issues Coexisting medical conditions Reproductive goals Sensitive exams can be based on individual risk assessment and preventative health care needs

Treatment Percentage of treated individuals is a function of the organization they are a part of Insurance, cultural, health professional opinions, diagnostic procedure availability Psychosocial evaluation is critical

Array of Options Voice and communication therapy Help individuals develop verbal and nonverbal communication skills to facilitate comfort with gender identity Hair removal Breast binding or padding Genital tucking or penile prosthesis Padding of hips/buttocks Pubertal suppression Cross gender hormone therapy

Social Transitioning Social transition can sometimes be completed before puberty Success varies widely based on support of the family No evidence to predict long-term outcomes in completing this transition early in childhood Mental health professionals can be very helpful in this transitional time

Interventions Fully reversible GnRH analogues, progestin, spironolactone, COCs Partially reversible Masculinizing or feminizing hormones Some effects are not reversible without surgical correction Gynecomastia, deepening of voice Irreversible Surgical procedures

Fully Reversible Interventions Eligible for puberty-suppressing hormones as soon as pubertal changes noted Should at least experience Tanner 2 Remember this may be very young! Gives adolescents more time to explore their gender nonconformity Can prevent development of sex characteristics that can only be reversed surgically Pubertal suppression does not inevitably lead to transition or sex reassignment

Criteria for Pubertal Suppression The adolescent has demonstrated a longlasting and intense pattern of gender nonconformity or dysphoria Emerged or worsened with the onset of puberty Coexisting psychological, medical, or social problems that could interfere with treatment have been addressed Informed consent has been obtained

Follow up Protocol Every 3 months Anthropometry: height, weight, SMR Laboratory: LH, FSH, estradiol/testosterone Every year Laboratory: renal and liver function, lipids, glucose, insulin, glycosylated hemoglobin Bone density using dual-energy x-ray absorptiometry Bone age or x-ray of the left hand

The image part with relationship ID rid2 was not found in the file. Role for Hormones Denying access to hormones represents a refusal to recognize the humanity of trans people, frustrates their ability to self-determine their gender, infringes on personal autonomy, and adds to the cumulative effect of the constant discrimination they confront Gehl, 2007

Cross-gender Hormone Therapy MTF transsexual persons Estrogen: Oral: estradiol2.0 6.0 mg/d Transdermal: estradiol patch0.1 0.4 mg twice weekly Parenteral: estradiol valerate or cypionate 5 20 mg im every 2 wk2 10 mg im every week Antiandrogens: Spironolactone100 200 mg/d Cyproterone acetate 2 50 100 mg/d GnRH agonist: 3.75 mg sc monthly FTM transsexual persons Testosterone Oral: testosterone undecanoate 160 240 mg/d Parenteral: Testosterone enanthate or cypionate 100 200 mg IM every 2 wk or 50% weekly Testosterone undecanoate 23 1000 mg every 12 wk

Expected Effects of Masculinizing Hormones Skin oiliness/acne Facial/body hair growth Scalp hair loss Increased muscle mass/strength Body fat redistribution Cessation of menses Clitoral enlargement Vaginal atrophy Deepened voice

Expected Effects of Feminizing Hormones Body fat redistribution Decreased muscle mass/strength Softening of skin/decreased oiliness Decreased libido Decreased spontaneous erections Male sexual dysfunction Breast growth Decreased testicular volume Decreased sperm production Thinning of facial and body hair Male pattern baldness

Surveillance (MTF) 1. Evaluate patient every 2 3 months in the first year and then 1 2 times per year afterward to monitor for appropriate signs of feminization and for development of adverse reactions. 2. Measure serum testosterone and estradiol every 3 months. a. Serum testosterone levels should be <55 ng/dl. b. Serum estradiol should not exceed the peak physiological range for young healthy females, with ideal levels <200 pg/ml. c. Doses of estrogen should be adjusted according to the serum levels of estradiol. 3. For individuals on spironolactone, serum electrolytes (particularly potassium) should be monitored every 2 3 months initially in the first year. 4. Routine cancer screening is recommended in nontranssexual individuals (breasts, colon, prostate). 5. Consider BMD testing at baseline if risk factors for osteoporotic fracture are present (e.g. previous fracture, family history, glucocorticoid use, prolonged hypogonadism). In individuals at low risk, screening for osteoporosis should be conducted at age 60 and in those who are not compliant with hormone therapy.

Surveillance (FTM) 1. Evaluate patient every 2 3 months in the first year and then 1 2 times per year to monitor for appropriate signs of virilization and for development of adverse reactions. 2. Measure serum testosterone every 2 3 months until levels are in the normal physiological male range: 1 - For testosterone enanthate/cypionate injections, the testosterone level should be measured midway between injections. If the level is >700 ng/dl or <350 ng/dl, adjust dose accordingly. - For parenteral testosterone undecanoate, testosterone should be measured just before the next injection. - For transdermal testosterone, the testosterone level can be measured at any time after 1 wk. - For oral testosterone undecanoate, the testosterone level should be measured 3 5 h after ingestion. - Note: During the first 3 9 months of testosterone treatment, total testosterone levels may be high, although free testosterone levels are normal, due to high SHBG levels in some biological women. 3. Measure estradiol levels during the first 6 months of testosterone treatment or until there has been no uterine bleeding for 6 months. Estradiol levels should be <50 pg/ml. 4. Measure complete blood count and liver function tests at baseline and every 3 months for the first year and then 1 2 times a year. Monitor weight, blood pressure, lipids, fasting blood sugar (if family history of diabetes), and hemoglobin A1c (if diabetic) at regular visits. 5. Consider BMD testing at baseline if risk factors for osteoporotic fracture are present (e.g. previous fracture, family history, glucocorticoid use, prolonged hypogonadism). In individuals at low risk, screening for osteoporosis should be conducted at age 60 and in those who are not compliant with hormone therapy. 6. If cervical tissue is present, an annual pap smear is recommended by the American College of Obstetricians and Gynecologists. 7. If mastectomy is not performed, then consider mammograms as recommended by the American Cancer Society.

Appropriate Scenarios for Provision of Hormones Bridging Hormone therapy following gonad removal Hormone maintenance prior to gonad removal Hormone initiation

Surgical Considerations For many, sex reassignment surgery is medically necessary Relief of gender dysphoria can t be accomplished without it Surgical outcomes are generally favorable Improved well being, cosmesis, and sexual function Mental health is reliably improved DeCuypere, 2005

Surgical Considerations Breast and genital surgery should be performed only after assessment by qualified mental health professionals Medically necessary based on gender dysphoria diagnosis 12 months of hormone therapy is typically recommended prior to performing any irreversible procedures

MTF Surgical Options Breast/chest surgery: augmentation mammoplasty Genital surgery: penectomy, orchiectomy, vaginoplasty, clitoroplasty, vulvoplasty Feminizing procedures: facial feminization surgery, liposuction, lipofilling, voice surgery, thyroid cartilage reduction (tracheal shaving) gluteal augmentation

FTM Surgical Options Breast/chest surgery: subcutaneous mastectomy, chest contouring May be considered before age 18 Genital surgery: hysterectomy with salpingooophorectomy, metoidioplasty/phalloplasty

Appropriate Candidates Historically reserved for patients over age 18 Real-life experience has resulted in satisfactory social role change Individual is satisfied with hormonal effects One year of consistent and compliant hormone tx Individual desires definitive social change Endocrine Society, 2009

Resources for Health Professionals World Professional Organization for Transgender Health (WPATH) www.wpath.org The Center of Excellence for Transgender Health www.transhealth.ucsf.edu Endocrine Treatment of Transsexual Persons press.endocrine.org www.acog.org

Milwaukee Area Resources LGBT Community Center - mkelgbt.org - Gemini Gender Group -Project Q (youth) Wisconsin Rainbow Families - www.wirainbowfamilies.com Diverse and Resilient - www.diverseandresilient.org FORGE - www.forge-forward.org Uplasticsurgery.com

Madison Area Resources Outreach - www.lgbtoutreach.org UW-Madison Family Medicine Clinics (Resident Clinics; Children, teens & adults) Northeast Clinic - (608)241-9020 Wingra clinic - (608)263-3111 PATH (Pediatric and Adolescent Transgender Health) uwhealthkids.org Uplasticsurgery.com

References Gehl, PS, Arkles, F. Unraveling Injustice: Race and Class Impact of Medical Exclusions of Transition-Related Health Care for Transgender People. 4 Sexuality Res & Soc. Povy 7,12 (2007) Kitts, RL. (2010) Barriers to Optimal Care between Physicians and Lesbian, Gay, Bisexual, Transgender, and Questioning Adolescent Patients. Journal of Homosexuality, vol 57, issue 6: 73-747 Russell, S. T., Ryan, C., Toomey, R. B., Diaz, R. M. and Sanchez, J. (2011), Lesbian, Gay, Bisexual, and Transgender Adolescent School Victimization: Implications for Young Adult Health and Adjustment. Journal of School Health, 81: 223 230. Snelgrove JW, Jasudavisius AM, Rowe BW et al. Completely out-to-sea with two-gender medicine": A qualitative analysis of physician-side barriers to providing health care for transgender patients. BMC Health Services Research, 2012. 12:110 Press.endocrine.org www.cdc.gov www.minorityhealth.hhs.gov www.wpath.org www.acog.org

Questions?